| Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis (NCT03298581) | Sun Pharmaceutical Industries Limited | 2017-01-01 |
| Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy (NCT03000309) | Derm Research, PLLC | 2016-12-29 |
| Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects (NCT03018509) | Akros Pharma Inc. | 2016-12-01 |
| Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis (NCT03005964) | AmDerma | 2016-12-01 |
| A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis (NCT02886702) | Fougera Pharmaceuticals Inc. | 2016-09-19 |
| A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis (NCT02899988) | Eli Lilly and Company | 2016-09-14 |
| An Open Label, Safety Study to Assess the Potential for Adrenal Suppression (NCT02932878) | Sun Pharmaceutical Industries, Inc. | 2016-09-02 |
| Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test (NCT03004339) | DFB Soria, LLC | 2016-08-01 |
| Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis (NCT02826603) | Novartis Pharmaceuticals | 2016-06-22 |
| A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310) (NCT02742441) | Therapeutics, Inc. | 2016-06-01 |
| Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (NCT01815723) | Forward-Pharma GmbH | 2016-06-01 |
| Real-life Evaluation of the Daivobet® Gel Applicator (NCT02856542) | LEO Pharma | 2016-05-23 |
| Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast (NCT02749370) | Amgen | 2016-05-18 |
| Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients (NCT02908347) | MetrioPharm AG | 2016-05-01 |
| A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. (NCT02752776) | Novartis Pharmaceuticals | 2016-03-17 |
| Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis (NCT02749799) | Primus Pharmaceuticals | 2016-02-01 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment (NCT02634801) | Eli Lilly and Company | 2016-01-20 |
| ASIS for Enbrel in Plaque Psoriasis (NCT02112097) | ASIS Corporation | 2016-01-01 |
| Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis (NCT02514577) | Bausch Health Americas, Inc. | 2015-11-07 |
| Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis (NCT02515097) | Bausch Health Americas, Inc. | 2015-11-05 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (NCT02561806) | Eli Lilly and Company | 2015-10-01 |
| Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis (NCT02601469) | Sun Pharmaceutical Industries, Inc. | 2015-09-04 |
| Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis (NCT02618759) | Sun Pharmaceutical Industries, Inc. | 2015-08-28 |
| DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis (NCT02527421) | Primus Pharmaceuticals | 2015-08-19 |
| Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis (NCT02462122) | Bausch Health Americas, Inc. | 2015-08-19 |
| Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis (NCT02462083) | Bausch Health Americas, Inc. | 2015-08-11 |
| Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis (NCT02462070) | Bausch Health Americas, Inc. | 2015-08-11 |
| Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis (NCT02494479) | Cellceutix Corporation | 2015-08-01 |
| A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (NCT02513550) | Eli Lilly and Company | 2015-08-01 |
| Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (NCT02489227) | Coherus Oncology, Inc. | 2015-08-01 |
| A Long Term Safety Extension Study (CHS-0214-05) (NCT02486939) | Coherus Oncology, Inc. | 2015-07-01 |
| Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A (NCT02547714) | Novartis Pharmaceuticals | 2015-06-16 |
| Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis (NCT02412644) | Psoriasis Treatment Center of Central New Jersey | 2015-05-28 |
| Plaque Psoriasis Efficacy and Safety With Secukinumab (NCT02409667) | Novartis Pharmaceuticals | 2015-05-07 |
| A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study (NCT02413229) | Sun Pharmaceutical Industries, Inc. | 2015-04-01 |
| A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis. (NCT02486302) | Pfizer | 2015-03-24 |
| Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (NCT02346240) | UCB Biopharma S.P.R.L. | 2015-02-11 |
| Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis (NCT02340169) | Sun Pharmaceutical Industries, Inc. | 2015-01-23 |
| Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis (NCT02274792) | Amgen | 2015-01-01 |
| A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306) (NCT02368210) | Therapeutics, Inc. | 2015-01-01 |
| Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis (NCT02701205) | Shanghai Celgen Bio-Pharmaceutical Co.,Ltd | 2015-01-01 |
| A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (NCT02367911) | Therapeutics, Inc. | 2015-01-01 |
| Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis (NCT02098213) | Association Francaise pour la Recherche Thermale | 2015-01-01 |
| An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (NCT02326298) | UCB Biopharma S.P.R.L. | 2014-12-16 |
| A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (NCT02326272) | UCB Biopharma S.P.R.L. | 2014-12-15 |
| A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation (NCT02310750) | Pfizer | 2014-11-01 |
| Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis (NCT02201524) | Pfizer | 2014-11-01 |
| A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis (NCT02435342) | Kineta Inc. | 2014-10-01 |
| Evaluate the Effect of Elimune Capsules (NCT02251678) | Elorac, Inc. | 2014-09-01 |
| Plaque Psoriasis Study in Pediatric Subjects (NCT02186665) | Galderma R&D | 2014-07-01 |
| Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) (NCT02134210) | Coherus Oncology, Inc. | 2014-06-16 |
| Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis (NCT02129777) | Takeda | 2014-06-01 |
| Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis (NCT02160665) | G & W Laboratories Inc. | 2014-05-01 |
| Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis (NCT02243787) | Covagen | 2014-04-01 |
| Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis (NCT02239666) | AstraZeneca | 2014-03-01 |
| TSO for Plaque Psoriasis (NCT02011269) | Coronado Biosciences, Inc. | 2014-03-01 |
| Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis (NCT02045277) | Bausch Health Americas, Inc. | 2014-02-01 |
| A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (NCT02016482) | AbbVie | 2014-01-01 |
| DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (NCT02070965) | Primus Pharmaceuticals | 2014-01-01 |
| Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis (NCT02153840) | Guangdong Provincial Hospital of Traditional Chinese Medicine | 2013-12-01 |
| Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis (NCT02192164) | Pfizer | 2013-11-01 |
| Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients (NCT01989429) | Maruho Europe Limited | 2013-10-01 |
| Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT01987843) | Tanabe Pharma Corporation | 2013-09-01 |
| Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% (NCT01893567) | Galderma R&D | 2013-07-01 |
| Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept (NCT01875991) | Amgen | 2013-06-05 |
| A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305) (NCT01882647) | Therapeutics, Inc. | 2013-06-01 |
| A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis (NCT01899729) | Idera Pharmaceuticals, Inc. | 2013-05-01 |
| A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304) (NCT01871402) | Therapeutics, Inc. | 2013-05-01 |
| Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis (NCT01777191) | Eli Lilly and Company | 2013-03-01 |
| Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis (NCT01710046) | Pfizer | 2013-03-01 |
| PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis (NCT01766440) | Galderma R&D | 2013-03-01 |
| A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (NCT01729754) | Sun Pharmaceutical Industries Limited | 2013-02-05 |
| Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (NCT01768858) | AbbVie | 2013-02-05 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (NCT01722331) | Sun Pharmaceutical Industries Limited | 2012-12-06 |
| LAS41008 in Moderate to Severe Chronic Plaque Psoriasis (NCT01726933) | Almirall, S.A. | 2012-11-01 |
| Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris (NCT01707043) | Wake Forest University | 2012-10-01 |
| Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation (NCT01707368) | LEO Pharma | 2012-10-01 |
| Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (NCT01708629) | Bausch Health Americas, Inc. | 2012-09-01 |
| Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis (NCT01646073) | AbbVie (prior sponsor, Abbott) | 2012-08-01 |
| A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis (NCT01558310) | Paul Steven Yamauchi, MD, PhD | 2012-08-01 |
| A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis (NCT01680159) | Tanabe Pharma Corporation | 2012-07-01 |
| A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis (NCT01634087) | Incyte Corporation | 2012-06-01 |
| A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 (NCT01670513) | Dow Pharmaceutical Sciences | 2012-06-01 |
| A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis (NCT01700985) | Therapeutics, Inc. | 2012-05-01 |
| A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF (NCT01566578) | Ennar Pharmaceuticals AF | 2012-04-01 |
| Adalimumab-psoriasis and Small Bowel Lesions (NCT01556672) | Innovaderm Research Inc. | 2012-04-01 |
| Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression (NCT01698333) | Therapeutics, Inc. | 2012-04-01 |
| A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis (NCT01610596) | Therapeutics, Inc. | 2011-11-01 |
| Trial of CF101 to Treat Patients With Psoriasis (NCT01265667) | Can-Fite BioPharma | 2011-07-01 |
| Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis (NCT01321164) | Medical University of Vienna | 2011-04-01 |
| Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients (NCT01301157) | Maruho Co., Ltd. | 2011-02-01 |
| Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis (NCT01279629) | Glenmark Farmacêutica Ltda | 2011-02-01 |
| A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis (NCT01373567) | Piramal Enterprises Limited | 2010-12-01 |
| A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate (NCT01251614) | AbbVie (prior sponsor, Abbott) | 2010-12-01 |
| Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. (NCT01232283) | Amgen | 2010-11-22 |
| A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022) (NCT01235728) | Merck Sharp & Dohme LLC | 2010-11-01 |
| Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (NCT01194219) | Amgen | 2010-09-09 |
| To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis (NCT00747032) | Fougera Pharmaceuticals Inc. | 2010-09-01 |
| Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis (NCT01230138) | Forward-Pharma GmbH | 2010-09-01 |
| Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis (NCT01166646) | Therapeutics, Inc. | 2010-07-01 |